Table II.

HIV-1-specific immune responses demonstrated to date in the 16 HIV-1-resistanta study subjectsb

Study SubjectCervical ELISPOTcPBMC ELISPOTcHIV-1 env Th ResponsedHIV-1 env Bulk CTLeHIV-1 Peptide Bulk CTLfHIV-1-Specific Mucosal IgAgHIV-1-Neutralizing Mucosal IgAh
ML8511111
ML889111
ML12500011
ML1260101001
ML12750111
ML135601
ML1358000001
ML14371101
ML148811
ML14901111
ML15891111
ML1601111
ML162211
ML16430011
ML17921110
ML180311011
  • a HIV-1 resistance as defined by Fowke et al. (26).

  • b “1” indicates a positive assay result, and “0” indicates a negative result. Where a space is left blank, the assay has not been previously performed.

  • c See text for definition of a positive cervical and PBMC ELISPOT.

  • d Defined as an IL-2 stimulation index of ≥ 4 in response to stimulation by two or more antigenic HIV-1 envelope peptides (7).

  • e Defined as >10% specific lysis by bulk CTL line of autologous BCL, infected by HIV-1 env/vaccinia construct (16).

  • f Defined as >10% specific lysis by bulk CTL line of autologous BCL, pulsed with class I HLA-restricted HIV-1 CTL epitope (15).

  • g Defined as levels of HIV-1-specific cervical or vaginal IgA >2 SD above mean levels found in low-risk Kenyan controls (7).

  • h Defined as ≥2/3 (67%) reduction of clade B HIV-1 p24 in culture supernatant, in the presence of purified mucosal IgA (34).